Adaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.33), $0.02 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $44.87 million.

GUIDANCE:

Adaptive Biotechnologies sees FY2023 revenue of $205-215 million, versus the consensus of $207.2 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.